272 related articles for article (PubMed ID: 8418243)
1. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
[TBL] [Abstract][Full Text] [Related]
2. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
[TBL] [Abstract][Full Text] [Related]
3. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer.
Powles T; Paterson S; Kanis JA; McCloskey E; Ashley S; Tidy A; Rosenqvist K; Smith I; Ottestad L; Legault S; Pajunen M; Nevantaus A; Männistö E; Suovuori A; Atula S; Nevalainen J; Pylkkänen L
J Clin Oncol; 2002 Aug; 20(15):3219-24. PubMed ID: 12149294
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
5. Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
Kanis JA; Powles T; Paterson AH; McCloskey EV; Ashley S
Bone; 1996 Dec; 19(6):663-7. PubMed ID: 8968035
[TBL] [Abstract][Full Text] [Related]
6. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
[TBL] [Abstract][Full Text] [Related]
7. Treatment of skeletal disease in breast cancer with clodronate.
Paterson AH; Ernst DS; Powles TJ; Ashley S; McCloskey EV; Kanis JA
Bone; 1991; 12 Suppl 1():S25-30. PubMed ID: 1720012
[TBL] [Abstract][Full Text] [Related]
8. [Double-blind trial of oral clodronate in breast cancer patients with bone metastases].
Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
Bull Cancer; 1993; 80(10 Suppl):50-6. PubMed ID: 8081032
[No Abstract] [Full Text] [Related]
9. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
O'Rourke N; McCloskey E; Houghton F; Huss H; Kanis JA
J Clin Oncol; 1995 Apr; 13(4):929-34. PubMed ID: 7707121
[TBL] [Abstract][Full Text] [Related]
10. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
[TBL] [Abstract][Full Text] [Related]
11. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
12. Clodronate: a review of its use in breast cancer.
Hurst M; Noble S
Drugs Aging; 1999 Aug; 15(2):143-67. PubMed ID: 10495073
[TBL] [Abstract][Full Text] [Related]
13. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
14. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
[TBL] [Abstract][Full Text] [Related]
15. Oral clodronate in breast cancer patients with bone metastases: a randomized study.
Kristensen B; Ejlertsen B; Groenvold M; Hein S; Loft H; Mouridsen HT
J Intern Med; 1999 Jul; 246(1):67-74. PubMed ID: 10447227
[TBL] [Abstract][Full Text] [Related]
16. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases.
Paterson AH
Cancer; 2000 Jun; 88(12 Suppl):3038-46. PubMed ID: 10898349
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial.
Saarto T; Blomqvist C; Virkkunen P; Elomaa I
J Clin Oncol; 2001 Jan; 19(1):10-7. PubMed ID: 11134190
[TBL] [Abstract][Full Text] [Related]
19. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
20. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study.
Robertson AG; Reed NS; Ralston SH
J Clin Oncol; 1995 Sep; 13(9):2427-30. PubMed ID: 7666103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
